ClinicalTrials.gg
RecruitingNCT06449703Updated Jun 10, 2024

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects

A Phase 1 interventional study of insulin degludec/liraglutide and Xultophy® in Healthy, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-10.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The main purpose of the trial is to compare the pharmacokinetics of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared with Xultophy®. During the trial period, serials of blood samples will be collected from the participants at two dosing periods, in order to determine the concentration of insulin degludec and liraglutide. The total volume of blood taken throughout the whole trial period will be less than 400 mL. Participants will be asked to stay on daytime and overnight in the trial sites on some predefined days. For other outpatient days, participants need to attend the trial site as required for drug administration or required assessments.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tonghua Dongbao Pharmaceutical Co.,Ltd is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects signed and dated form (ICF) before having a full understanding of the study contents and procedures and potential adverse reactions for the study;
  2. Subjects are able to communicate well with the investigator and complete the study;
  3. Subjects (including partners) have no pregnancy plan and voluntarily take effective measures (For details of the contraceptive measures, see Appendix II) from screening to within 6 months after the last dose of study drug;
  4. Healthy Chinese subjects aged 18 to 45 years (inclusive), male or female;
  5. (BMI) ≥ 19 kg/m2 and ≤ 26kg/m2 at screening, male weight ≥ 50 kg, females weight≥ 45 kg;
  6. Fasting blood glucose \< 6.1 mmol/L at screening;
  7. Normal or abnormal but not physical examination and vital signs at screening.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. A history of allergy to the ingredients of medical product or other glucagon-like peptide-1 (GLP-1) analogues and their , or a history of severe drug or food allergy;
  2. A history of fainting during acupuncture treatment and blood phobia and physical condition unable to withstand blood collection, poor vein condition leading to infeasibility of establishment of blood collection pathway, and difficulty in venous blood collection;
  3. Females breast-feeding, or females with a positive blood pregnancy test result at screening;
  4. Individuals who have participated in clinical trials of drugs or medical devices within 3 months prior to screening, defined as whose who have used other investigational products or devices;
  5. Individuals who have undergone surgery within 3 months prior to screening, which may affect the safety of subjects or the evaluation of the study results as judged by the investigator, or those who have undergone surgery within 1 month prior to screening or plan to undergo surgery during the study;
  6. Donated > 400 mL of blood or donated any blood component or had a total blood loss of > 400 mL for any reason within 3 months prior to screening, or those who have a history of blood transfusion, use of blood products or who cannot guarantee not donating whole blood or blood components (e.g., plasma, ) during the study or within 30 days after the end of the study;
  7. Abnormal and clinical laboratory test results, or with the following clinically significant diseases as indicated by other clinical findings within 12 months prior to screening, including but not limited to circulatory, digestion, respiratory, endocrine, urinary, nervous, blood and immune system disorders or psychiatric disorders;
  8. A history of diabetes mellitus in the past;
  9. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2;
  10. A history of pancreatitis (acute or chronic) in the past;
  11. Thrombotic diseases in the past (e.g., with a medical history of pulmonary embolism and deep venous thrombosis or superficial vein thrombosis not cured or cured within 6 months prior to enrollment) or currently with new thrombotic diseases or using anticoagulants;
  12. Abnormal and clinically significant 12-Lead ;
  13. Abnormal and clinically significant calcitonin test at screening;
  14. Positive for any of (HIV) antibody, virus surface antigen (HBsAg), virus antibody (HCVAb) or treponema pallidum antibody;
  15. A history of drug abuse in the past 5 years or have engaged in drug taking or been tested positive for breath alcohol test or urine drug screening within 3 months prior to screening;
  16. A history of smoking (average daily smoking>5 cigarettes) within 3 months prior to screening and cannot quit during the study;
  17. In the three months before screening, the intake of alcohol more than 14 units every week (1 unit ≈ 360 mL of beer, 45 mL of spirits with alcohol content ≥ 40% or 150 mL of wine) and cannot quit during the study;
  18. Those who drink excessive amounts of tea, coffee and/or caffeinated beverages (over 8 cups, with 1 cup ≈ 250 mL) every day within 3 months prior to screening and cannot quit during the study;
  19. Individuals who have used any prescription drug, non-prescription drug (except for occasional or restrictive use of paracetamol), health product (except for conventional vitamin supplements and calcium) within 14 days prior to screening, or those who have used any traditional herb containing unknown or unspecified components within 3 months prior to screening;
  20. Individuals who have received any GLP-1 drug within 3 months prior to screening;
  21. Individuals who have received any vaccination within 1 month prior to screening, or plan to receive any vaccination during the study;
  22. Individuals who still need or plan to engage in strenuous physical activities or exercise during participation in the study;
  23. Any other factor not suitable for participation in this clinical study as judged by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Insulin Degludec/Liraglutide

    Drug: insulin degludec/liraglutide

  • Active comparator
    Xultophy®

    Drug: Xultophy®

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.

  • DrugXultophy®

    Xultophy®

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma insulin degludec concentration

    Calculated based on insulin degludec measured in plasma

    Time frame: 0 hours to 120 hours

  2. Maximum observed plasma liraglutide concentration

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  3. Area under the plasma insulin degludec concentration time curve

    Calculated based on insulin degludec concentration in plasma

    Time frame: From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide, assessments from 0 hours to 120 hours

  4. Area under the plasma liraglutide concentration time curve

    Calculated based on liraglutide concentration in plasma

    Time frame: From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide, assessments from 0 hours to 72 hours

  5. Area under the plasma insulin degludec concentration time curve from 0 to infinity after single dose

    Calculated based on insulin degludec measured in plasma

    Time frame: 0 hours to 120 hours

  6. Area under the plasma liraglutide concentration time curve from 0 to infinity after single dose

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

Secondary outcomes

  1. Time to maximum plasma insulin degludec concentration

    Calculated based on insulin degludec measured in plasma

    Time frame: 0 hours to 120 hours

  2. Time to maximum plasma liraglutide concentration

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  3. Terminal elimination half-life for insulin degludec

    Calculated based on insulin degludec measured in plasma

    Time frame: 0 hours to 120 hours

  4. Terminal elimination half-life for liraglutide

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  5. Apparent clearance for insulin degludec

    Calculated based on insulin degludec measured in plasma

    Time frame: 0 hours to 120 hours

  6. Apparent clearance for liraglutide

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  7. Apparent volume of distribution for insulin degludec

    Calculated based on insulin degludec measured in plasma

    Time frame: 0 hours to 120 hours

  8. Apparent volume of distribution for liraglutide

    Calculated based on liraglutide measured in plasma

    Time frame: 0 hours to 72 hours

  9. Area under the plasma insulin degludec concentration time curve

    Calculated based on insulin degludec concentration in plasma

    Time frame: 0 hours to 24 hours

  10. Number of treatment emergent adverse events

    Count

    Time frame: From the first drug administration to the follow-up visit (6 to 13 days after the last drug administration)

  11. Number of treatment emergent hypoglycaemic episodes

    Count

    Time frame: From the first drug administration to the follow-up visit (6 to 13 days after the last drug administration)

  12. Number of participants with injection site reactions (spontaneous pain, tenderness, itching, redness, edema, induration/infiltration)

    Count

    Time frame: From the first drug administration to the follow-up visit (6 to 13 days after the last drug administration)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jun 2024, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2024
First posted
Jun 10, 2024
StartActual
May 6, 2024
Primary completionEst.
Jun 16, 2024
CompletionEst.
Jun 16, 2024
Last update
Jun 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06449703
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
May 6, 2024
Primary completion
Jun 16, 2024 (estimated)
Completion
Jun 16, 2024 (estimated)
Last update
Jun 10, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion